US 10221244
Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 10221244 (Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer) held by Five Prime Therapeutics, Inc. expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Five Prime Therapeutics, Inc.
- Grant date
- Tue Mar 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 31
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K2039/54, A61K2039/545